Pneumonia caused by coliforms and Pseudomonas aeruginosa
- PMID: 824327
- PMCID: PMC476135
- DOI: 10.1136/jcp.29.7.652
Pneumonia caused by coliforms and Pseudomonas aeruginosa
Abstract
The diagnosis and treatment of 20 hospital patients seen in the past year with proven pneumonia caused by coliforms and Pseudomonas aeruginosa are discussed. Predisposing factors and methods for improving laboratory and clinical diagnosis are analysed, the main problem being to discriminate between genuine pneumonia caused by these organisms and mere contamination of sputum samples resulting from colonization of the upper respiratory tract following broad-spectrum chemotherapy. Overall initial chemotherapy with gentamicin cured 75% (15 out of 20) of the patients in spite of unfavourable underlying pathology. Where gentamicin was given in adequate dosage, which in practice meant that dose which produced peak serum concentrations of 8 mug/ml or more, the cure rate was 91% (11 out of 12). In those patients achieving (measured) peak serum concentrations of less than 8 mug/ml the cure rate was only 33% (4 out of 12). These figures include four patients who failed to respond to doses of gentamicin producing peak concentrations of 5-0-6-0 mug/ml in each case. These patients responded promptly to higher doses (or accumulation), producing peak serum concentrations of 8 mug/ml or more and were then cured within three to five days. Toxicity from gentamicin was not observed in any patient. These results indicate that it is necessary to monitor gentamicin therapy by laboratory assay to ensure adequate dosage and that peak serum concentrations of 8 mug/ml or more are significantly correlated with successful treatment of pneumonia caused by coliforms and Ps. aeruginosa.
Similar articles
-
Gentamicin-resistant bacillary infection. Clinical features and amikacin therapy.Arch Intern Med. 1978 Feb;138(2):201-5. Arch Intern Med. 1978. PMID: 415674
-
Combined aztreonam and gentamicin therapy for pseudomonal lower respiratory tract infections.Clin Ther. 1994 Mar-Apr;16(2):236-52. Clin Ther. 1994. PMID: 8062319 Clinical Trial.
-
Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis.Br Med J. 1974 Mar 16;1(5906):477-81. doi: 10.1136/bmj.1.5906.477. Br Med J. 1974. PMID: 4206128 Free PMC article.
-
[Pneumonia caused by Pseudomonas aeruginosa].Pol Tyg Lek. 1971 May 10;26(19):725-6. Pol Tyg Lek. 1971. PMID: 4997246 Review. Polish. No abstract available.
-
[Gentamicin resistance in clinical strains of microorganisms: genetic control and biochemical mechanisms of resistance].Antibiot Med Biotekhnol. 1985 Jan;30(1):65-75. Antibiot Med Biotekhnol. 1985. PMID: 3922292 Review. Russian. No abstract available.
Cited by
-
Klebsiella: taxonomy, nomenclature, and communication.J Clin Pathol. 1977 Oct;30(10):943-4. doi: 10.1136/jcp.30.10.943. J Clin Pathol. 1977. PMID: 338633 Free PMC article. Review.
-
Unusual acute lupus hemophagocytic syndrome - a test of diagnostic criteria: a case report.J Med Case Rep. 2017 Jul 7;11(1):185. doi: 10.1186/s13256-017-1339-7. J Med Case Rep. 2017. PMID: 28683778 Free PMC article.
-
Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored?Clin Pharmacokinet. 1999 Feb;36(2):89-98. doi: 10.2165/00003088-199936020-00001. Clin Pharmacokinet. 1999. PMID: 10092956 Review.
-
Therapeutic drug monitoring of aminoglycoside antibiotics.Infection. 1980;8 Suppl 3:S 313-20. doi: 10.1007/BF01639603. Infection. 1980. PMID: 6997210 Review.
-
A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing.Clin Pharmacokinet. 1980 May-Jun;5(3):295-306. doi: 10.2165/00003088-198005030-00007. Clin Pharmacokinet. 1980. PMID: 7389237
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous